Mesoblast (MESO) Competitors $11.26 -0.28 (-2.43%) Closing price 04:00 PM EasternExtended Trading$11.06 -0.21 (-1.82%) As of 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MESO vs. TGTX, TLX, VRNA, LNTH, AXSM, GRFS, NUVL, ADMA, PCVX, and KRYSShould you be buying Mesoblast stock or one of its competitors? The main competitors of Mesoblast include TG Therapeutics (TGTX), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Verona Pharma (VRNA), Lantheus (LNTH), Axsome Therapeutics (AXSM), Grifols (GRFS), Nuvalent (NUVL), ADMA Biologics (ADMA), Vaxcyte (PCVX), and Krystal Biotech (KRYS). These companies are all part of the "pharmaceutical products" industry. Mesoblast vs. TG Therapeutics Telix Pharmaceuticals Limited American Depositary Shares Verona Pharma Lantheus Axsome Therapeutics Grifols Nuvalent ADMA Biologics Vaxcyte Krystal Biotech TG Therapeutics (NASDAQ:TGTX) and Mesoblast (NASDAQ:MESO) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, community ranking, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk. Is TGTX or MESO more profitable? Mesoblast has a net margin of 0.00% compared to TG Therapeutics' net margin of -5.42%. Mesoblast's return on equity of 0.00% beat TG Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets TG Therapeutics-5.42% -8.32% -3.40% Mesoblast N/A N/A N/A Do analysts prefer TGTX or MESO? TG Therapeutics presently has a consensus target price of $40.80, indicating a potential upside of 19.30%. Mesoblast has a consensus target price of $18.00, indicating a potential upside of 59.86%. Given Mesoblast's stronger consensus rating and higher probable upside, analysts clearly believe Mesoblast is more favorable than TG Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TG Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Mesoblast 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has more risk & volatility, TGTX or MESO? TG Therapeutics has a beta of 2.21, indicating that its stock price is 121% more volatile than the S&P 500. Comparatively, Mesoblast has a beta of 2.5, indicating that its stock price is 150% more volatile than the S&P 500. Does the media favor TGTX or MESO? In the previous week, TG Therapeutics had 5 more articles in the media than Mesoblast. MarketBeat recorded 11 mentions for TG Therapeutics and 6 mentions for Mesoblast. TG Therapeutics' average media sentiment score of 1.56 beat Mesoblast's score of 0.50 indicating that TG Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TG Therapeutics 11 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Mesoblast 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings & valuation, TGTX or MESO? TG Therapeutics has higher revenue and earnings than Mesoblast. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTG Therapeutics$386.39M14.05$12.67M$0.24142.50Mesoblast$5.67M253.75-$87.96MN/AN/A Do insiders & institutionals believe in TGTX or MESO? 58.6% of TG Therapeutics shares are owned by institutional investors. Comparatively, 1.4% of Mesoblast shares are owned by institutional investors. 10.6% of TG Therapeutics shares are owned by insiders. Comparatively, 18.8% of Mesoblast shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community favor TGTX or MESO? TG Therapeutics received 245 more outperform votes than Mesoblast when rated by MarketBeat users. Likewise, 76.27% of users gave TG Therapeutics an outperform vote while only 70.41% of users gave Mesoblast an outperform vote. CompanyUnderperformOutperformTG TherapeuticsOutperform Votes65976.27% Underperform Votes20523.73% MesoblastOutperform Votes41470.41% Underperform Votes17429.59% SummaryMesoblast beats TG Therapeutics on 9 of the 17 factors compared between the two stocks. Get Mesoblast News Delivered to You Automatically Sign up to receive the latest news and ratings for MESO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MESO vs. The Competition Export to ExcelMetricMesoblastBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.44B$2.93B$5.35B$8.38BDividend YieldN/A1.72%5.22%4.10%P/E RatioN/A30.5026.8419.71Price / Sales253.75400.15391.39116.98Price / CashN/A168.6838.2534.62Price / Book2.673.286.794.50Net Income-$87.96M-$72.17M$3.23B$248.18M7 Day Performance-2.43%4.28%4.07%1.14%1 Month Performance9.53%7.62%12.52%15.20%1 Year Performance42.35%-28.15%16.83%6.56% Mesoblast Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MESOMesoblast1.8344 of 5 stars$11.26-2.4%$18.00+59.9%+57.9%$1.44B$5.67M0.0080Gap DownTGTXTG Therapeutics3.8254 of 5 stars$34.99+4.0%$40.80+16.6%+115.2%$5.56B$386.39M-349.87290Positive NewsTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$16.25-5.4%$22.00+35.4%N/A$5.49B$783.21M0.00N/AGap DownVRNAVerona Pharma2.6693 of 5 stars$67.53+6.6%$81.50+20.7%+484.7%$5.48B$118.54M-35.1730Positive NewsLNTHLantheus4.458 of 5 stars$79.52-2.7%$132.67+66.8%-7.3%$5.45B$1.54B13.23700Positive NewsHigh Trading VolumeAXSMAxsome Therapeutics4.7175 of 5 stars$110.16+2.2%$172.14+56.3%+39.7%$5.42B$432.16M-18.39380Positive NewsInsider TradeGRFSGrifols3.2195 of 5 stars$7.73+8.9%N/A+4.7%$5.31B$7.21B6.6126,300Positive NewsNUVLNuvalent2.6421 of 5 stars$73.63+5.4%$115.50+56.9%+7.0%$5.27BN/A-21.2240News CoveragePositive NewsADMAADMA Biologics3.1796 of 5 stars$20.45+2.4%$24.25+18.6%+117.2%$4.86B$459.38M73.04530News CoveragePositive NewsGap DownPCVXVaxcyte3.0977 of 5 stars$31.59+1.4%$136.50+332.1%-51.8%$4.08BN/A-6.87160News CoveragePositive NewsEarnings ReportGap UpKRYSKrystal Biotech4.8856 of 5 stars$139.43+5.5%$218.63+56.8%-20.0%$4.03B$333.45M46.63210 Related Companies and Tools Related Companies TGTX Competitors TLX Competitors VRNA Competitors LNTH Competitors AXSM Competitors GRFS Competitors NUVL Competitors ADMA Competitors PCVX Competitors KRYS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MESO) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mesoblast Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Mesoblast With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
